

May 15, 2026

Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 (Under Japanese GAAP)

Company name: JEOL Ltd.
 Listing: Tokyo Stock Exchange
 Securities code: 6951
 URL: <https://www.jeol.co.jp>
 Representative: Izumi Oi, President & CEO
 Inquiries: Toshihiko Kanayama, Director & Officer; General Manager, Management Strategy Planning Division
 Telephone: +81-42-543-1111
 Scheduled date of annual general meeting of shareholders: June 25, 2026
 Scheduled date to commence dividend payments: June 26, 2026
 Scheduled date to file annual securities report: June 23, 2026
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for institutional investors and securities analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended March 31, 2026 (from April 1, 2025 to March 31, 2026)

(1) Consolidated operating results

(Percentages indicate year-on-year changes.)

Fiscal year ended	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2026	179,353	(8.8)	26,017	(26.7)	28,610	(16.9)	22,097	18.2
March 31, 2025	196,695	12.8	35,501	28.9	34,424	14.7	18,688	(13.9)

Note: Comprehensive income For the fiscal year ended March 31, 2026: ¥26,796 million [59.6%]
 For the fiscal year ended March 31, 2025: ¥16,789 million [(38.0)%]

Fiscal year ended	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating profit to net sales
	Yen	Yen	%	%	%
March 31, 2026	432.58	-	15.7	12.3	14.5
March 31, 2025	365.55	-	14.3	15.2	18.0

Reference: Share of profit (loss) of entities accounted for using equity method
 For the fiscal year ended March 31, 2026: ¥462 million
 For the fiscal year ended March 31, 2025: ¥353 million

(2) Consolidated financial position

As of	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
March 31, 2026	242,026	144,898	59.9	2,975.26
March 31, 2025	222,486	136,653	61.4	2,672.19

Reference: Equity
 As of March 31, 2026: ¥144,898 million
 As of March 31, 2025: ¥136,653 million

(3) Consolidated cash flows

Fiscal year ended	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
March 31, 2026	16,000	(13,762)	(1,552)	37,326
March 31, 2025	23,104	(855)	(17,116)	34,605

2. Cash dividends

	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended March 31, 2025	-	44.00	-	62.00	106.00	5,449	29.0	4.1
Fiscal year ended March 31, 2026	-	53.00	-	79.00	132.00	6,614	30.5	4.7
Fiscal year ending March 31, 2027 (Forecast)		66.00		66.00	132.00		30.5	

Note: The year-end dividend per share for the fiscal year ended March 31, 2026 was changed from 53 yen to 79 yen . For details, please refer to the "Notice Concerning Dividends of Surplus (Increase in Dividend)" announced today (May 15, 2026).

3. Forecast of consolidated financial results for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending September 30, 2026	63,000	(23.2)	6,000	(49.7)	5,700	(55.8)	4,200	(57.4)	85.31
Fiscal year ending March 31, 2027	164,000	(8.6)	26,500	1.9	26,200	(8.4)	21,300	(3.6)	432.64

* **Notes**

- (1) Significant changes in the scope of consolidation during the period: None
- (2) Changes in accounting policies, changes in accounting estimates, and restatement
- (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None
- (iv) Restatement: None
- (3) Number of issued shares (common shares)

- (i) Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2026	51,532,800 shares
As of March 31, 2025	51,532,800 shares

- (ii) Number of treasury shares at the end of the period

As of March 31, 2026	2,831,561 shares
As of March 31, 2025	393,904 shares

- (iii) Average number of shares outstanding during the period

Fiscal year ended March 31, 2026	51,083,490 shares
Fiscal year ended March 31, 2025	51,123,935 shares

[Reference] Overview of non-consolidated financial results

1. Non-consolidated financial results for the fiscal year ended March 31, 2026 (from April 1, 2025 to March 31, 2026)

(1) Non-consolidated operating results

(Percentages indicate year-on-year changes.)

Fiscal year ended	Net sales		Operating profit		Ordinary profit		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2026	147,144	(11.0)	21,875	(32.2)	26,279	(20.4)	20,956	14.9
March 31, 2025	165,279	13.1	32,286	26.5	33,007	12.4	18,231	(13.9)

Fiscal year ended	Basic earnings per share	Diluted earnings per share
	Yen	Yen
March 31, 2026	410.24	-
March 31, 2025	356.61	-

(2) Non-consolidated financial position

As of	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
March 31, 2026	201,408	127,440	63.3	2,616.78
March 31, 2025	186,501	124,280	66.6	2,430.26

Reference: Equity

As of March 31, 2026: ¥127,440 million

As of March 31, 2025: ¥124,280 million

* Financial results reports are exempt from audit conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

(Cautions on forward-looking statements, etc.)

Forward-looking statements, such as earnings forecasts, contained in this material are based on judgments made by the Company and the Group based on information available to the Company and the Group at the time of publication, but include risks and uncertainties. Actual results may differ from forecasts due to various factors such as the economic environment surrounding the Company, market trends, and fluctuations in exchange rates.

(How to obtain supplementary explanatory materials for financial results)

The Company plans to hold a briefing for institutional investors and analysts on Friday, May 29, 2026. Supplementary financial results briefing materials will be posted on the Company's website after the date of the financial results briefing.

Consolidated balance sheet

(Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Assets		
Current assets		
Cash and deposits	36,144	38,949
Notes and accounts receivable - trade, and contract assets	51,717	50,503
Merchandise and finished goods	15,932	17,145
Work in process	55,599	53,489
Raw materials and supplies	5,486	4,895
Refundable income taxes receivable	145	61
Consumption taxes receivable	3,065	4,096
Other	2,219	2,371
Allowance for doubtful accounts	(819)	(968)
Total current assets	169,492	170,545
Non-current assets		
Property, plant and equipment		
Buildings and structures	30,461	32,025
Accumulated depreciation	(20,852)	(21,950)
Buildings and structures, net	9,609	10,074
Machinery, equipment and vehicles	7,385	5,836
Accumulated depreciation	(5,667)	(4,819)
Machinery, equipment and vehicles, net	1,717	1,016
Tools, furniture and fixtures	29,761	35,214
Accumulated depreciation	(23,651)	(26,988)
Tools, furniture and fixtures, net	6,109	8,226
Land	3,952	4,048
Leased assets	4,680	5,118
Accumulated depreciation	(3,143)	(3,341)
Leased assets, net	1,536	1,777
Construction in progress	1,183	12,784
Total property, plant and equipment	24,108	37,927
Intangible assets		
Software	804	685
Goodwill	911	785
Other	2,060	3,424
Total intangible assets	3,776	4,895
Investments and other assets		
Investment securities	14,769	16,753
Retirement benefit asset	-	3,583
Deferred tax assets	8,500	6,518
Other	1,847	1,810
Allowance for doubtful accounts	(7)	(7)
Total investments and other assets	25,109	28,658
Total non-current assets	52,994	71,481
Total assets	222,486	242,026

	As of March 31, 2025	As of March 31, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	11,197	9,412
Electronically recorded obligations - operating	4,677	4,269
Short-term borrowings	-	14,000
Current portion of long-term borrowings	4,413	3,267
Lease liabilities	574	601
Accounts payable - other	3,486	3,382
Income taxes payable	6,039	3,005
Accrued consumption taxes	455	614
Contract liabilities	34,035	29,767
Provision for bonuses	2,156	2,055
Other	5,958	9,084
Total current liabilities	72,995	79,462
Non-current liabilities		
Long-term borrowings	3,170	7,903
Lease liabilities	1,127	1,331
Deferred tax liabilities	223	198
Provision for retirement benefits for directors (and other officers)	51	56
Provision for share awards for directors (and other officers)	665	728
Retirement benefit liability	6,846	6,649
Asset retirement obligations	370	377
Other	384	420
Total non-current liabilities	12,838	17,665
Total liabilities	85,833	97,127
Net assets		
Shareholders' equity		
Share capital	21,394	21,394
Capital surplus	21,271	21,271
Retained earnings	86,163	102,348
Treasury shares	(688)	(13,327)
Total shareholders' equity	128,140	131,686
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	4,295	5,136
Deferred gains or losses on hedges	(1)	(87)
Foreign currency translation adjustment	2,843	5,046
Remeasurements of defined benefit plans	1,374	3,116
Total accumulated other comprehensive income	8,512	13,211
Total net assets	136,653	144,898
Total liabilities and net assets	222,486	242,026

Consolidated statement of income

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Net sales	196,695	179,353
Cost of sales	104,297	96,323
Gross profit	92,397	83,030
Selling, general and administrative expenses		
Research and development expenses	11,978	11,405
Other	44,917	45,607
Total selling, general and administrative expenses	56,896	57,013
Operating profit	35,501	26,017
Non-operating income		
Interest income	249	272
Dividend income	228	229
Insurance claim income	3	77
Revenue from acceptance of development services	130	165
Share of profit of entities accounted for using equity method	353	462
Foreign exchange gains	-	1,423
Subsidy income	20	21
Reversal of allowance for doubtful accounts	123	2
Other	113	224
Total non-operating income	1,223	2,879
Non-operating expenses		
Interest expenses	120	133
Loss on sale of trade receivables	2	2
Loss on cancellation of insurance policies	49	-
Foreign exchange losses	1,952	-
Commission expenses	-	40
Amortization of share issuance costs	15	-
Other	158	111
Total non-operating expenses	2,300	286
Ordinary profit	34,424	28,610
Extraordinary income		
Gain on sale of non-current assets	26	100
Gain on sale of investment securities	2,789	1,016
Gain on step acquisitions	112	-
Total extraordinary income	2,928	1,117
Extraordinary losses		
Loss on sale of non-current assets	3	1
Loss on retirement of non-current assets	5	4
Loss on valuation of investment securities	12,381	0
Impairment losses	-	232
Total extraordinary losses	12,389	239
Profit before income taxes	24,962	29,488
Income taxes - current	10,070	7,435
Income taxes - deferred	(3,795)	(44)
Total income taxes	6,274	7,390
Profit	18,688	22,097
Profit attributable to owners of parent	18,688	22,097

Consolidated statement of comprehensive income

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Profit	18,688	22,097
Other comprehensive income		
Valuation difference on available-for-sale securities	(1,902)	840
Deferred gains or losses on hedges	149	(86)
Foreign currency translation adjustment	(398)	2,026
Remeasurements of defined benefit plans, net of tax	216	1,742
Share of other comprehensive income of entities accounted for using equity method	35	176
Total other comprehensive income	(1,898)	4,699
Comprehensive income	16,789	26,796
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	16,789	26,796
Comprehensive income attributable to non-controlling interests	-	-

Consolidated statement of changes in equity

Fiscal year ended March 31, 2025

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	21,394	21,271	73,284	(847)	115,102
Changes during period					
Dividends of surplus			(5,809)		(5,809)
Profit attributable to owners of parent			18,688		18,688
Purchase of treasury shares				(1)	(1)
Disposal of treasury shares				160	160
Net changes in items other than shareholders' equity					-
Total changes during period	-	-	12,878	159	13,038
Balance at end of period	21,394	21,271	86,163	(688)	128,140

	Accumulated other comprehensive income					Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	
Balance at beginning of period	6,198	(151)	3,207	1,157	10,411	125,513
Changes during period						
Dividends of surplus					-	(5,809)
Profit attributable to owners of parent					-	18,688
Purchase of treasury shares					-	(1)
Disposal of treasury shares					-	160
Net changes in items other than shareholders' equity	(1,902)	149	(363)	216	(1,898)	(1,898)
Total changes during period	(1,902)	149	(363)	216	(1,898)	11,139
Balance at end of period	4,295	(1)	2,843	1,374	8,512	136,653

Consolidated statement of changes in equity

Fiscal year ended March 31, 2026

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	21,394	21,271	86,163	(688)	128,140
Changes during period					
Dividends of surplus			(5,912)		(5,912)
Profit attributable to owners of parent			22,097		22,097
Purchase of treasury shares				(12,770)	(12,770)
Disposal of treasury shares				132	132
Net changes in items other than shareholders' equity					-
Total changes during period	-	-	16,185	(12,638)	3,546
Balance at end of period	21,394	21,271	102,348	(13,327)	131,686

	Accumulated other comprehensive income					Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	
Balance at beginning of period	4,295	(1)	2,843	1,374	8,512	136,653
Changes during period						
Dividends of surplus					-	(5,912)
Profit attributable to owners of parent					-	22,097
Purchase of treasury shares					-	(12,770)
Disposal of treasury shares					-	132
Net changes in items other than shareholders' equity	840	(86)	2,202	1,742	4,699	4,699
Total changes during period	840	(86)	2,202	1,742	4,699	8,245
Balance at end of period	5,136	(87)	5,046	3,116	13,211	144,898

Consolidated statement of cash flows

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Cash flows from operating activities		
Profit before income taxes	24,962	29,488
Depreciation	4,925	5,369
Amortization of goodwill	253	141
Increase (decrease) in provision for bonuses	94	(118)
Increase (decrease) in retirement benefit liability	145	202
Increase (decrease) in provision for retirement benefits for directors (and other officers)	8	5
Increase (decrease) in provision for share awards for directors (and other officers)	173	195
Loss (gain) on sale and retirement of non-current assets	(17)	(95)
Loss (gain) on sale of investment securities	(2,789)	(1,016)
Loss (gain) on valuation of investment securities	12,381	0
Loss (gain) on step acquisitions	(112)	-
Share of loss (profit) of entities accounted for using equity method	(353)	(462)
Subsidy income	(20)	(21)
Impairment losses	-	232
Interest and dividend income	(478)	(502)
Interest expenses	120	133
Loss on sales of notes and accounts receivable-trade	2	2
Decrease (increase) in trade receivables	4,423	2,467
Decrease (increase) in inventories	2,233	1,575
Increase (decrease) in trade payables	(13,855)	(3,685)
Increase/decrease in consumption taxes payable/consumption taxes refund receivable	356	(893)
Increase (decrease) in contract liabilities	(1,422)	(6,419)
Other, net	171	(763)
Subtotal	31,202	25,830
Interest and dividends received	480	503
Interest paid	(136)	(93)
Payment for the sale of notes and accounts receivable-trade-paid	(2)	(2)
Income taxes refund (paid)	(9,772)	(10,259)
Subsidies received	1,332	21
Net cash provided by (used in) operating activities	23,104	16,000

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Cash flows from investing activities		
Decrease (increase) in time deposits	135	(21)
Proceeds from sale of investment securities	3,041	1,122
Purchase of property, plant and equipment	(2,960)	(13,489)
Proceeds from sale of property, plant and equipment	96	191
Purchase of intangible assets	(1,303)	(1,606)
Proceeds from sale of intangible assets	-	4
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(637)	-
Payments for acquisition of shares of unconsolidated subsidiaries	-	(20)
Proceeds from collection of long-term loans receivable	2	2
Payments for acquisition of businesses	(150)	-
Other, net	919	54
Net cash provided by (used in) investing activities	(855)	(13,762)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(3,900)	14,000
Proceeds from long-term borrowings	-	8,000
Repayments of long-term borrowings	(6,943)	(4,413)
Purchase of treasury shares	(1)	(12,770)
Dividends paid	(5,797)	(5,908)
Other, net	(474)	(459)
Net cash provided by (used in) financing activities	(17,116)	(1,552)
Effect of exchange rate change on cash and cash equivalents	(334)	2,036
Net increase (decrease) in cash and cash equivalents	4,797	2,721
Cash and cash equivalents at beginning of period	29,807	34,605
Cash and cash equivalents at end of period	34,605	37,326

(Notes on segment information, etc.)
[Segment Information]

1 Overview of Reporting Segments

The Group's reporting segments are those of the constituent units of the Group for which separate financial information is available and are subject to periodic review by the Board of Directors in order to determine the allocation of management resources and evaluate business performance.

The Group reports on three reporting segments: Scientific and Metrology Instruments, Industrial Equipment, and Medical Equipment, based on the classification of the Group's products according to the applications in which they are used.

The Scientific and Metrology Instruments segment manufactures and sells electron microscopes, nuclear magnetic resonance spectrometers, mass spectrometers, and other products. The Industrial Equipment segment manufactures and sells electron beam lithography system, electron beam metal AM machine (3D Printer), and high-frequency power supplies. The Medical Equipment segment manufactures and sells clinical chemistry analyzer and other products.

2. Method of calculating the amount of sales, profits or losses, assets, liabilities, and other items for each reporting segment

The method of accounting for the reported business segments is generally the same as described in the "Fundamental Important Matters for the Preparation of Consolidated Financial Statements".

Profit in the reporting segment is a figure based on operating income.

3 Information on the amount of sales, profits or losses, assets, liabilities and other items for each reported segment, and information on the breakdown of earnings

The previous fiscal year (April 1, 2024 to March 31, 2025)

(Millions of yen)

	Reportable segments				Adjustment amount (Note) 1	Amount recorded in consolidated financial statements (Note)2
	Scientific and Metrology Instruments	Industrial Equipment	Medical Equipment	Total		
Sales						
Japan	40,356	4,188	12,149	56,693	-	56,693
North, Central, and South America	21,290	4,122	2,755	28,167	-	28,167
China	24,646	19,808	330	44,785	-	44,785
other	38,500	28,363	183	67,047	-	67,047
Revenue generated from customer contracts	124,793	56,483	15,418	196,695	-	196,695
Revenues from external customers	124,793	56,483	15,418	196,695	-	196,695
Transactions with other segments	-	-	-	-	-	-
Total	124,793	56,483	15,418	196,695	-	196,695
Segment Profit	15,017	26,316	662	41,997	(6,495)	35,501
Segment Assets	109,551	51,372	13,909	174,834	47,652	222,486
Other items						
Depreciation	3,012	1,249	325	4,587	337	4,925
Increase in property, plant and equipment and intangible assets	3,750	1,857	235	5,844	1,186	7,030

Note: 1. The amount of adjustment is as follows.

(1) The adjustment for segment profit of (6,495) million yen includes (6,495) million yen of company-wide expenses that have not been allocated to each reporting segment. Company-wide expenses are mainly related to the Company's general administrative departments, such as the general affairs and accounting departments.

(2) Adjusted segment assets of 47,652 million are company-wide assets that have not been allocated to each reporting segment. Company-wide assets consist mainly of residual funds under management (cash and deposits) and long-term investment funds (investment securities).

(3) The adjustment for depreciation and amortization of 337 million is a depreciation expense for the Company's General and Administrative Division, which is not attributable to the Reporting Segment.

(4) The adjustment amount of 1,186 million yen for the increase in property, plant and equipment and intangible assets is a company-wide asset that has not been allocated to each reporting segment.

2. Segment profit is adjusted to operating income in the consolidated statements of income.

	Reportable segments				Adjustment amount (Note) 1	Amount recorded in consolidated financial statements (Note)2
	Scientific and Metrology Instruments	Industrial Equipment	Medical Equipment	Total		
Sales						
Japan	40,237	6,854	11,695	58,788	-	58,788
North, Central, and South America	20,855	4,426	2,354	27,636	-	27,636
China	18,496	16,470	642	35,609	-	35,609
other	36,705	20,379	234	57,319	-	57,319
Revenue generated from customer contracts	116,295	48,131	14,926	179,353	-	179,353
Revenues from external customers	116,295	48,131	14,926	179,353	-	179,353
Transactions with other segments	-	-	-	-	-	-
Total	116,295	48,131	14,926	179,353	-	179,353
Segment Profit	13,069	19,363	64	32,497	(6,479)	26,017
Segment Assets	122,827	51,345	18,002	192,176	49,850	242,026
Other items						
Depreciation	3,333	1,417	318	5,069	299	5,369
Increase in property, plant and equipment and intangible assets	15,493	2,801	335	18,629	1,552	20,182

Note: 1. The amount of adjustment is as follows.

(1) The adjustment for segment profit of (6,479) million yen includes (6,479) million yen of company-wide expenses that have not been allocated to each reporting segment. Company-wide expenses are mainly related to the Company's general administrative departments, such as the general affairs and accounting departments.

(2) Adjusted segment assets of 49,850 million are company-wide assets that have not been allocated to each reporting segment. Company-wide assets consist mainly of residual funds under management (cash and deposits) and long-term investment funds (investment securities).

(3) The adjustment for depreciation and amortization of 299 million is a depreciation expense for the Company's General and Administrative Division, which is not attributable to the Reporting Segment.

(4) The adjustment amount of 1,552 million yen for the increase in property, plant and equipment and intangible assets is a company-wide asset that has not been allocated to each reporting segment.

2. Segment profit is adjusted to operating income in the consolidated statements of income.

[Information on impairment losses on fixed assets by reporting segment]

The previous fiscal year (April 1, 2024 to March 31, 2025)
Not applicable.

The current fiscal year (April 1, 2025 to March 31, 2026)

(Millions of yen)

	Reportable segments				Unallocated amounts and elimination	Total
	Scientific and Metrology Instruments	Industrial Equipment	Medical Equipment	Total		
Impairment Loss	-	232	-	232	-	232

[Information on amortization and unamortized balances of goodwill by reporting segment]

The previous fiscal year (April 1, 2024 to March 31, 2025)

(Millions of yen)

	Reportable segments				Unallocated amounts and elimination	Total
	Scientific and Metrology Instruments	Industrial Equipment	Medical Equipment	Total		
Depreciation for the period	203	49	-	253	-	253
Balance at the end of the current fiscal year	683	228	-	911	-	911

The current fiscal year (April 1, 2025 to March 31, 2026)

(Millions of yen)

	Reportable segments				Unallocated amounts and elimination	Total
	Scientific and Metrology Instruments	Industrial Equipment	Medical Equipment	Total		
Depreciation for the period	93	47	-	141	-	141
Balance at the end of the current fiscal year	596	188	-	785	-	785